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The inhibition of 5-[3H]hydroxytryptamine uptake into rat forebrain synaptosomes by human plasma 
extracts was studied. Highly potent, small (MI < lOOOO), and heat stable factor(s) were found to inhibit 
5-[3H]hydroxytryptamine uptake specifically, reversibly and in a non-competitive manner. The possible 
role of these factor(s) as endogenous modulators of serotonergic activity is discussed. 
5-Hydroxytryptamine uptake Plasma factor Synaptosome Imipramine 
Endogenous modulator 
1. INTRODUCTION 
Serotonin (5hydroxytryptamine; 5HT) is ac- 
cumulated into the presynaptic nerve terminal by a 
specific high affinity transport process [l]. The 
postulated role of this transport system is to ter- 
minate the synaptic action of 5HT and to regulate 
its concentration in the synaptic cleft [2]. An- 
tidepressant drugs, such as imipramine, inhibit the 
uptake of 5HT into nerve terminals, a process 
which has been considered to be of major impor- 
tance for their antidepressant effects. Imipramine 
has been shown in both brain preparations [3,4] 
and platelets [5] to inhibit serotonin uptake 
specifically by binding to a site which is structural- 
ly and functionally associated with the 5HT 
transporter (so-called [3H]imipramine binding 
site). Nevertheless, it is not clear whether these 
sites are identical to the 5HT recognition site, as 
some pharmacological studies have suggested, or 
are allosteric sites which are functionally coupled 
to the 5HT transporter [6-81. Clinical studies in 
severely depressed patients have demonstrated 
alterations in the density of [3H]imipramine bind- 
ing sites and in the ability of platelets to ac- 
cumulate [3H]5HT [9-l 11. One possible explana- 
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tion for these changes is the differential presence 
of humoral endogenous modulators of the 
transport system. Thus, if the [3H]imipramine 
binding site serves to allosterically modulate 
(inhibit or enhance) serotonin transport, the 
presence of endogenous effecters of these sites is 
plausible. We here report the presence and prelim- 
inary characterization of substance(s) in blood that 
inhibit synaptosomal [3H]5HT uptake and also in- 
hibit [3H]imipramine binding. 
2. MATERIALS AND METHODS 
2.1. Preparation of crude synaptosomes 
Adult male Osborne-Mendel rats (180-250 g) 
were killed by decapitation and their forebrains 
(whole brain minus cerebellum) were pooled and 
homogenized in 20 vols of 0.32 M sucrose. All 
procedures were carried out on ice at 0-4°C. The 
homogenate was centrifuged (1000 x g, 10 min) 
and the supernatant was further centrifuged at 
17000 x g for 30 min. The resulting supernatant 
was decanted and the pellet (Pz) was resuspended 
in 20 vols of 0.32 M sucrose. 
2.2. Measurement of neurotransmitter uptake 
The uptake of several neurotransmitters into the 
crude synaptosomal preparation was assayed using 
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a modification of the methods in [ 1,2]. Briefly, 
0.2 ml crude synaptosomes were preincubated for 
10 min at 37’C with 0.7 ml of either Krebs-Ringer 
buffer (NaCI, 120 mM; KCI, 4.8 mM; CaC12, 
2.3 mM, MgSO4, 1.2 mM; dextrose, 2 mg/ml; 
containing EDTA, 0.06 mg/ml; Pargyline, 10 FM; 
ascorbic acid, 0.2 mg/ml, KzHP04, 15.6 mM, pH 
7.4) or varying volumes of the blood extract 
prepared in the same buffer in a total assay volume 
of 1 .O ml. The reaction was started by the addition 
of 0.1 ml aliquots of radiolabelled neurotransmit- 
ter at a final concentration of approx. 40 nM 
(spec. act. t3H]5HT, 23.4 Cilmmol; [3H]dopa- 
mine, 30.4 Ci/mmol; [3H]norepinephrine, 43.9 
Ci/mmol and [3H]GABA, 38.0 Ci/mmol; all from 
NEN, Boston, MA). After a 2 min incubation at 
37°C the reaction was stopped by dilution with 
4 ml ice-cold Krebs-Ringer buffer and by rapid 
filtration under reduced pressure, using Whatman 
GF/C filters (0.45 pm pore size). The filters were 
further rinsed 3 times with 4 ml ice-cold buffer and 
the radioactivity on the filters counted in a 
Beckman LS 9000 scintillation counter. Net up- 
take was calculated by subtracting parallel assay 
tubes incubated at 0°C. 
pond to the initial rate of uptake. 
As demonstrated in fig.1, addition of a very 
small aliquot of the plasma extract induced a 
marked inhibition of [3H]5HT uptake. Under the 
assay conditions described, as little as 25 ~1 of 
plasma extract inhibited the uptake of t3H]5HT by 
50%, whereas about 200~1 completely inhibited 
the uptake. Very similar dose-response curves were 
also obtained using untreated plasma, serum or 
boiled serum (not shown). 
Kinetic analysis of [3H]5HT uptake into 
forebrain synaptosomes and the effect of various 
plasma concentrations are shown in fig.2. Using 
[3H]5HT concentrations ranging from 4-400 nM, 
a single saturable high affinity uptake site was 
found. This transport process has an apparent &, 
of 60 nM and a Vmax of 5 pmol/mg protein per 
min. Fig.2 demonstrates that the inhibitory effect 
of boiled plasma was non-competitive in nature 
(e.g., there is no apparent change in the affinity of 
13H]5HT to its transporter, but the V,,, of 
transport is markedly reduced). Thus the in- 
hibitory factor(s) in plasma do not directly com- 
pete with t3H]5HT for the transport recognition 
site, but rather interact with the transport system 
2.3. Preparation of blood extracts I I , / 5 I 
Blood was obtained from medication-free 
volunteers by venipuncture and collected in tubes 
containing 16 mM citrate buffer and 1 mM 
EDTA. Cellular elements were separated by low- 
speed centrifugation (600 x g, 10 min) and the 
plasma separated by further centrifugation at 
12000 x g for 20 min. Plasma was subsequently 
diluted I : 4 with Krebs-Ringer buffer and boiled 
for 10 min at 90°C. After cooling, the denatured 
proteins were separated by centrifugation at 20000 
x g for 20 min and the supernatant fluid was 
collected. 
3. RESULTS 
! I I I I I I 
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The effects of diluted and boiled human plasma 
on 13H15HT uptake into rat forebrain synap- 
tosomes were studied. In this synaptosomal 
preparation, [3Hf5HT uptake was linear with in- 
cubation time up to 3 min and plateaued at ap- 
prox. 10 min (not shown). The data presented here 
represent 2 min incubations and therefore corres- 
Fig.1. The effect(s) of human plasma extract on 
13H]5HT uptake in rat brain synaptosomes. Uptake of 
[3H]5HT in the absence and presence of various plasma 
concentrations was carried out at 37°C for 2 min at 
40 nM [3H]SHT as described in the text. Values are the 
mean * SE of at least 23 separate experiments. The 
control value for net [“H]SHT uptake was 2.08 + 
0.07 pmol-mg protein-’ amin-r. 
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Fig.2. Kinetic analysis of the effect of various plasma 
concentrations on [3H]SHT uptake into forebrain 
synaptosomes. The uptake of various [3H]5HT 
concentrations was conducted for 2 min at 37°C and 
0.4 mg synaptosomal protein/ml. Non-specific uptake 
was measured at 0°C and corresponds to less than 10% 
of total uptake. (0) Control, (0) 25 ~1 plasma, (0) 
100~1 plasma. Values are from a representative 
experiment repeated 3 times with similar results. 
through other mechanisms. Since the presence of 
endogenous inhibitors of (Na+ + K+)-ATPase in 
human blood has been demonstrated [ 121 and since 
these inhibitors would be expected to non- 
specifically inhibit any (Na+ + K+)-ATPase- 
dependent transport system we examined whether 
the present uptake inhibition was specific for 
[3H]5HT. 
The effect of the plasma extract on the transport 
of other neurotransmitters into synaptosomes was 
studied, and the extract volumes resulting in 50% 
inhibition of uptake (IGO) were calculated and are 
shown in table 1. 
Significantly greater amounts of plasma extract 
were necessary to inhibit the specific transport of 
t3H]dopamine, [3H]norepinephrine or [3H]GABA 
into synaptosomes. The plasma extract volume re- 
quired to inhibit 50% of [3H]dopamine or 
[3H]norepinephrine uptake, is approx. 10 times 
greater than that for inhibiting [‘H]SHT uptake 
whereas approx. 6-7 times more plasma is 
necessary to produce a similar inhibition of 
[‘HIGABA uptake. These data indicate that the 
plasma factor(s) are more selective for the 
blockade of [3H]5HT uptake, and that they may be 
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Table 1 
Effect of plasma extract on the uptake of different 
neurotransmitters 
Neurotransmitter n zc50 bl) 
[3H]5HT 17 28* 4 
[3H]Dopamine 6 340 f 86 
[3H]Norepinephrine 6 367 + 81 
[3H]GABA 8 192 2 23 
Specific uptake of the neurotransmitters was carried out 
as described. ZCso values representing the volume of 
plasma (in al) which caused 50% inhibition of ‘H- 
labeled neurotransmitter uptake (each at 40 nM), were 
calculated from dose-response curves using at least 7 
concentrations of plasma. Values represent he mean + 
SE of the indicated number of separate experiments 
different from the endogenous (Na+ + K+)- 
ATPase inhibitors. 
Further characterization of the effect of plasma 
extract on [3H]5HT uptake has revealed that the 
inhibition is fully reversible (table 2). Synap- 
Table 2 
Reversibility of plasma extract-induced inhibition of 
synaptosomal [3H]5HT uptake 
[3H]5HT uptake Plasma OIo Control 
(pm01 . mg W) 
protein-‘. 
min- ‘) 
Control 2.78 + 0.38 - 
25 45.5 ?I 0.4 
100 27.0 + 2.4 
Pretreated with 2.55 + 0.17 - 
plasma 25 49.5 f 0.4 
100 26.5 f 2.0 
Crude synaptosomes (4 ml) were incubated with 1 ml of 
either Krebs-Ringer buffer or plasma extract for 10 min 
at 37°C. Subsequently both membrane preparations 
were washed twice by centrifugation at 17000 x g for 
20 min, resuspended in 5 ml of 0.32 M sucrose, and 
assayed for [3H]5HT uptake (at 40 nM) as described. 
Data represent means + SE of 3 experiments. 
Membranes pre-treated with plasma extract sufficient to 
inhibit 2 80% of specific [3H]5HT uptake had the same 
basal uptake rate after washing as control membranes. 
Subsequent inhibition by plasma extract was also similar 
in pretreated and control membranes 
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tosomes incubated with plasma extract at a con- 
centration sufficient to inhibit [3H]5HT uptake 
completely showed no significant difference in 
[3H]5HT uptake after washing and resuspension in 
the original buffer. Furthermore, no difference 
was found in the ability of previously incubated 
synaptosomes to be inhibited by newly added 
plasma extract (table 2). This finding rules out the 
possibility that the inhibition of [3H]5HT uptake is 
due to a non-specific detergent-like effect of the 
plasma extract that may have physically disrupted 
the integrity of the synaptosomal membrane. 
4. DISCUSSION 
This study reports the presence of factor(s) in 
human plasma, which inhibit the transport of 
t3H]5HT into rat forebrain synaptosomes and 
presents a preliminary characterization of this ef- 
fect. Since rather crude plasma preparations were 
used, it is at present not known whether a single 
factor or multiple substances are responsible for 
the observed effects. Nevertheless, that the ob- 
served inhibition was not due to several known 
candidates was ruled out. One possible candidate 
for an endogenous inhibitor of [3H]5HT uptake is 
5HT itself. 5HT is stored in rather high concentra- 
tions in platelets [13] and is also found free in 
plasma. Nevertheless, the human plasma concen- 
trations reported for 5HT are rather low, approx. 
70 nM [14], whereas the ZC~O for 5HT on [3H]5HT 
uptake using our assay conditions was found to be 
approx. 200 nM (not shown). Since the ZC~O of 
plasma on [3H]5HT uptake was shown to be about 
25 ~1 (table 1, fig.l), the plasma concentration of 
5HT would need be approx. 8 pM to elicit the same 
effect. Furthermore, we have shown (fig.2) that 
the inhibitory effect of the plasma factor(s) is non- 
competitive in nature, whereas 5HT inhibits 
[3H]5HT uptake competitively (not shown). 
Another candidate for an endogenous inhibitor of 
[3H]5HT uptake is the endogenous ouabain- and 
digitalis-like inhibitor of (Na+ + K+)-ATPase, 
which has also been shown to be present in plasma 
[12]. This circulating ATPase inhibitor has been 
associated with renal sodium excretion [ 151 and 
with essential hypertension [16]. Recently such in- 
hibitors have been shown to inhibit [3H]5HT up- 
take into human blood platelets [17] and 
[‘Hlnorepinephrine uptake into canine saphenous 
vein [18]. However, this substance(s) appears to be 
a rather non-specific inhibitor of (Na+ + K+)- 
ATPase, and therefore would be expected to un- 
couple many transport systems. Consequently, it is 
likely that the plasma factor(s) reported here are 
not endogenous ouabain-like substances, since in- 
hibition was rather specific for [3H]5HT uptake, as 
opposed to the uptake of other neurotransmitters, 
that are similarly dependent on the activity of 
(Na+ + K+)-ATPase. Furthermore, the endogen- 
ous (Na+ + K+)-ATPase inhibitor is reported to be 
several orders of magnitude less potent than the 
[3H]5HT uptake inhibitor reported here. For ex- 
ample, at least 10 vol. of plasma extract were 
necessary to produce 50% inhibition of [3H]5HT 
transport into platelets by the endogenous 
(Na+ + K+)-ATPase inhibitor [17], whereas only 
0.025 vols of plasma extract results in an 
equivalent inhibition of synaptosomal [3H]5HT 
uptake by the factor(s) reported here. Hence, it ap- 
pears unlikely that the factor(s) reported here are 
similar to the previously reported ATPase in- 
hibitor(s). 
Preliminary purification and characterization of 
the plasma factor(s) indicate that it is heat stable, 
and partially resistant o proteolytic cleavage. Us- 
ing ultrafiltration and dialysis, the inhibitory ac- 
tivity (not shown) has been shown to have a small 
A4, (< 10000). 
At present, the possible physiological signi- 
ficance of the inhibitory factor(s) is unknown. 
However, since preliminary experiments uggest a 
parallel inhibition of [3H]5HT uptake and [‘Hlim- 
ipramine binding to synaptosomal membranes, 
this material could represent an endogenous 
imipramine-like substance, and could have a role 
in regulating serotonergic activity. 
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